Physician profile
Stephen T Pyles
NPI 1386638674
$115,284.26
in general payments reported to CMS, 2019-2025
55 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $12K · 2021: $13K · 2022: $18K · 2023: $8,140 · 2024: $11K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $10K · Consulting Fee: $2,613 · Travel and Lodging: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,975.00 |
| Food and Beverage | $10,187.22 |
| Consulting Fee | $2,612.50 |
| Travel and Lodging | $1,765.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $80,380.28 | 2019-2025 | Wavewriter Alpha Prime 16, Clinical Trial Product, General - Pain Management |
| Stimwave Technologies Incorporated | $15,949.54 | 2019-2022 | |
| Nevro Corp. | $2,367.75 | 2019-2024 | Senza |
| Medtronic, INC. | $2,064.63 | 2021-2025 | Intellis Adaptivestim, Venaseal |
| Vertos Medical, INC. | $2,011.06 | 2019-2022 | |
| Vertiflex, INC. | $1,947.85 | 2019 | |
| Abbott Laboratories | $1,616.35 | 2019-2025 | Proclaim, Axium |
| Painteq LLC | $1,577.80 | 2021-2024 | Painteq |
| Kowa Pharmaceuticals America, INC. | $1,310.08 | 2022-2023 | Seglentis |
| Abbvie INC. | $789.17 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $639.91 | 2019-2025 | Xtampza, Belbuca |
| Saluda Medical Americas, INC. | $357.31 | 2024-2025 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.89 | 2020-2025 | Relistor |
| E.R. Squibb & Sons, L.L.C. | $328.10 | 2023-2025 | Zeposia |
| Lundbeck LLC | $237.52 | 2024-2025 | Vyepti |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$524,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.